Remote Follow-Up

In addition to offering physicians and patients a new level of freedom, this unique system supports efficient follow-up schemes based on either in person follow-up or remote monitoring as recommended by the HRS/EHRA expert consensus.

The current HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices recommends in person follow-ups after implantation and annual follow-ups. During the maintenance phase of follow-ups and when the patient's medical condition is stable and no anticipated device programming is required, follow-ups can be accomplished remotely.¹
 

The clinical landmark trial TRUST has clearly established the safety and effectiveness of remote monitoring. The results demonstrated that BIOTRONIK Home Monitoring safely reduces in-office follow-ups by 45%.²

In support of the HRS/EHRA expert consensus, and based on the TRUST landmark study results, BIOTRONIK Home Monitoring is the only remote monitoring system with FDA & CE mark approval for safe reduction of in-office follow-ups and early detection of clinically relevant events.

 

¹ B. Wilkoff, A. Auricchio, J. Brugada, M. Cowie, K. Ellenbogen, A. Gillis, D. Hayes, J. Howlett, J. Kautzner, C. Love, J. Morgan, S. Priori, D. Reynolds, M. Schoenfeld, P. Vardas: HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations, Europace 2008, 10(6): 707–725; doi:10.1093/europace/eun122

² Varma N, Epstein AE, Irimpen A, Schweikert R, Love C, for the TRUST investigators. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: The Lumos-T safely reduces routine office device follow-up (TRUST) Trial. Circulation. 2010;122:325-332